Patents by Inventor Hans-Peter Deigner
Hans-Peter Deigner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11313866Abstract: A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.Type: GrantFiled: September 11, 2017Date of Patent: April 26, 2022Assignee: InfanDx AGInventors: Matthias Keller, Hans-Peter Deigner, David Enot, Matthias Kohl, Ronnaug Solberg, Olga Saugstad, Therese Koal
-
Publication number: 20180011111Abstract: A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.Type: ApplicationFiled: September 11, 2017Publication date: January 11, 2018Applicant: InfanDx AGInventors: Matthias Keller, Hans-Peter Deigner, David Enot, Matthias Kohl, Ronnaug Solberg, Olga Saugstad, Therese Koal
-
Patent number: 9791459Abstract: A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.Type: GrantFiled: May 4, 2010Date of Patent: October 17, 2017Assignee: InfanDx AGInventors: Matthias Keller, Hans-Peter Deigner, David Enot, Matthias Kohl, Ronnaug Solberg, Ola Didrik Saugstad, Therese Koal
-
Method and Use of Metabolites for the Diagnosis of Inflammatory Brain Injury in Preterm Born Infants
Publication number: 20140297195Abstract: The present invention relates to novel biomarkers for predicting the likelihood of inflammation-related brain injury in preterm born infants, using a plurality of endogenous target metabolites selected from the group consisting of acyl carnitins, diacylphosphatidylcholines, acyl-alkylphosphatidylchoines, lysophosphatidylcholines and amino acids.Type: ApplicationFiled: February 22, 2012Publication date: October 2, 2014Applicant: InfanDx AGInventors: Matthias Keller, Carina Mallard, Hans-Peter Deigner, David Enot, Emeka I. Igwe -
Patent number: 8481262Abstract: The invention relates to a method for separating and/or enriching prokaryotic DNA, comprising the following steps: a) contacting of at least one prokaryotic DNA that is in solution with a protein that bonds specifically to prokaryotic DNA, the protein being 25%-35% homologous with the wild-type CGPB protein, thus forming a protein-DNA complex; and b) separation of the complex. The invention also relates to a kit for carrying out said method.Type: GrantFiled: March 2, 2005Date of Patent: July 9, 2013Assignee: SIRS-Lab GmbHInventors: Karl-Hermann Schmidt, Eberhard Straube, Stefan Russwurm, Hans-Peter Deigner, Svea Sachse, Marc Lehmann
-
Publication number: 20120326025Abstract: The invention discloses the use of at least one substance selected from the group consisting of Phosphatidylcholine with diacyl residue sum C24:0 (PC aa C24:0); Phosphatidylcholine with diacyl residue sum C40:3 (PC ae C40:3); Phosphatidylcholine with diacyl residue sum C40:4 (PC ae C40:4); Lysophosphatidylcholine with acyl residue sum C26:0 (lysoPC a C26:0); Lysophosphatidylcholine with acyl residue sum C6:0 (lysoPC a C6:0); 13(S)-hydroxy-9Z,11E-octadecadienoic acid (13S-HODE); 12(S)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12S-HETE); 15(S)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid (15S-HETE); Leukotriene B4 (LTB4); Prostaglandin E2 (PGE2); Prostaglandin D2 (PGD2); 7?-Hydroxycholesterol (7aOHC); 7-Ketocholesterol (7KC); 5?,6?-Epoxycholesterol (5b,6b,EPC); 5g302,6g302-Epoxycholesterol (5a,6a,EPC); and 4?-Hydroxycholesterol (4BOHC); for prognosticating relapse of a prostate cancer (PCa) in a sample of a body fluid or a tissue sample of a PCa patient.Type: ApplicationFiled: January 28, 2011Publication date: December 27, 2012Applicant: IMG Institut fur Medizinische Genomforschung Planu ngsgesellschaftInventors: Klaus Weinberger, Hans-Peter Deigner, Emeka Ignatius Igwe, David Enot, Guido Dallmann, Helmut Klocker
-
Patent number: 8338099Abstract: The present invention relates to reference genes, primers, and probes for the normalization of gene expression analysis data from blood samples of a patient. The invention further relates to a method for the normalization of gene expression analysis data with the aid of reference genes, primers, or probes.Type: GrantFiled: February 28, 2008Date of Patent: December 25, 2012Assignee: SIRS-Lab GmbHInventors: Stefan Russwurm, Hans-Peter Saluz, Hans-Peter Deigner
-
Publication number: 20120208282Abstract: The present invention relates to the use of endogenous reference metabolites and a method for normalization of intensity data corresponding to amounts and/or concentrations of selected target metabolites in a biological sample of a mammalian subject, wherein said intensity data are obtained by a metabolomics analysis method with one or a plurality of endogenous reference metabolites, comprising carrying out at least one in vitro metabolomics analysis method of said selected target metabolites in said biological sample, simultaneously carrying out in the same sample a quantitative analysis of one or a plurality of endogenous reference metabolites or derivatives thereof, wherein said endogenous reference metabolites are such compounds in the biological sample which are present in the subject at an essentially constant level; and wherein said endogenous reference metabolites or derivatives thereof have a molecular mass less than 1500 Da.Type: ApplicationFiled: June 23, 2010Publication date: August 16, 2012Inventors: Hans-Peter Deigner, Matthias Kohl, Matthias Keller, Therese Koal, David Enot
-
Publication number: 20120202240Abstract: The present invention relates to a reliable and statistically significant method for predicting the likelihood of an onset of an inflammation associated organ failure from a biological sample of a mammalian subject in vitro, by means of a subject's quantitative metabolomics profile comprising a plurality of endogenous metabolites, and comparing it with a quantitative reference metabolomics profile of a plurality of endogenous organ failure predictive target metabolites in order to predict whether the subject is likely or unlikely to develop an organ failure. Furthermore, the invention relates to the usefulness of endogenous organ failure predictive target metabolites in such a method.Type: ApplicationFiled: July 23, 2010Publication date: August 9, 2012Inventors: Hans-Peter Deigner, Matthias Kohl, David Enot, Theresa Koal, Matthias Keller
-
Publication number: 20120136581Abstract: A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.Type: ApplicationFiled: May 4, 2010Publication date: May 31, 2012Inventors: Matthias Keller, Hans-Peter Deigner, David Enot, Matthias Kohl, Ronnaug Solberg, Olga Didrik Saugstad, Therese Koal
-
Publication number: 20120115138Abstract: The present invention relates to a method and kit for in vitro diagnosing a complex disease such as cancer, in particular, acute myeloid leukemia (AML), colon cancer, kidney cancer, prostate cancer; transient ischemic attack (TIA), ischemia, in particular stroke, hypoxia, hypoxic-ischemic encephalopathy, perinatal brain damage, hypoxic-ischemic encephalopathy of neotatals asphyxia; demyelinating disease, in particular, white-matter disease, periventricular leukoencephalopathy, multiple sclerosis, Alzheimer and Parkinson's disease; in a biological sample. For the diagnosis, use is made of measuring at least two different species of biomolecules and classifying the results by means of suitable classifier algorithms and other statistical procedures. With the present invention, a significant improvement of the reliability of e.g. expression profiles alone, are achieved.Type: ApplicationFiled: March 31, 2010Publication date: May 10, 2012Applicant: BIOCRATES LIFE SCIENCES AGInventors: Hans-Peter Deigner, Matthias Kohl, Matthias Keller, Therese Koal, Klaus Wwinberger
-
Publication number: 20100184608Abstract: The present invention relates to reference genes, primers, and probes for the normalization of gene expression analysis data from blood samples of a patient. The invention further relates to a method for the normalization of gene expression analysis data with the aid of reference genes, primers, or probes.Type: ApplicationFiled: February 28, 2008Publication date: July 22, 2010Applicant: SIRS-Lab GmbHInventors: Stefan Russwurm, Hans-Peter Saluz, Hans-Peter Deigner
-
Publication number: 20100086909Abstract: The invention relates to the use of gene expression profiles, obtained in vitro from a patient sample, for the generation of criteria for the prediction of an individual course of disease in sepsis. The invention is further of use for determining the probability of survival in sepsis, the assessment of the course of disease in sepsis during treatment and for the classification of sepsis patients.Type: ApplicationFiled: January 14, 2005Publication date: April 8, 2010Applicant: SIRS-LAB GMBHInventors: Stefan Russwurm, Hans-Peter Deigner
-
Publication number: 20080306346Abstract: A method in which the cleavage profile and size distribution of von Willebrand factor (VWF) multimers is analyzed, includes: providing a sample medium of human body fluids comprising a plurality of VWF multimers of different size; enrichment or purification of the VWF multimers by cryoprecipitation or chromatography to obtain a separated preparation of the VWF multimers from said sample medium; exposing the separated preparation of VWF multimers to a light source to produce signals obtained by vibrational spectroscopy; detecting said signals; transformation by mathematical alogrithms; generation of patterns based on computing of data of original resonance spectra and determining the cleavage profile and the size distribution of said separated VWF multimers by chemometrics; and acquisition of a databank obtained from healthy individuals for identifying subjects at risk of developing at least one of the following diseases: sepsis, coagulopathy, thrombotic disease, infection, and inflammation.Type: ApplicationFiled: June 7, 2007Publication date: December 11, 2008Inventors: Ralf A. Claus, Clemens Bockmeyer, Hans-Peter Deigner, Michaela Harz, Petra Roesch, Juergen Popp, Rainer Riesenberg
-
Publication number: 20080286763Abstract: The invention relates to a method for the in vitro discrimination between systemic inflammatory non-infectious conditions and systemic inflammatory infectious conditions.Type: ApplicationFiled: December 15, 2004Publication date: November 20, 2008Inventors: Stefan Russwurm, Hans-Peter Deigner
-
Publication number: 20080070235Abstract: The present invention relates to a method for in vitro detection of SIRS, sepsis and/or sepsis-like conditions. This method renders the evaluation of the severity and/or the therapeutic progress of sepsis and severe infections, in particular sepsis-like systemic infections possible. Further, the present invention relates to the use of recombinantly or synthetically prepared nucleic acid sequences or peptide sequences derived therefrom as calibrator in sepsis assays and/or for the evaluation of the effect and the toxicity during screening of the active agents and/or the preparation of therapeutics for the prevention and treatment of SIRS, sepsis, sepsis-like systemic inflammatory conditions and sepsis-like systemic infections.Type: ApplicationFiled: March 31, 2004Publication date: March 20, 2008Applicant: SIRS-Lab GMBHInventors: Stefan Russwurm, Konrad Reinhart, Hans-Peter Saluz, Eberhard Straube, Peter Zipfel, Hans-Peter Deigner
-
Publication number: 20080003568Abstract: The invention relates to a method for separating and/or enriching prokaryotic DNA, comprising the following steps: a) contacting of at least one prokaryotic DNA that is in solution with a protein that bonds specifically to prokaryotic DNA, said protein being 25%-35% homologous with the wild-type CGPB protein, thus forming a protein-DNA complex; and b) separation of the complex. The invention also relates to a kit for carrying out said method.Type: ApplicationFiled: March 2, 2005Publication date: January 3, 2008Inventors: Karl-Hermann Schmidt, Eberhard Straube, Stefan Russwurm, Hans-Peter Deigner, Svea Sachse, Marc Lehmann
-
Patent number: 7301043Abstract: Compounds for determining the activity of phospholipase A2, are described herein, and include embodiments having formula (1) wherein L1 is derived from an ether (R1—OR2)m, wherein R1 and R2 are independently selected and are derived from a hydrocarbon having 1 to 12 carbon atoms, with m being an integer from 1 to 4, or from a hydrocarbon R having 1 to 20 carbon atoms; F is unsubstituted or substituted pyrene as a flouraphore; Q is a quencher, and L2 is C(O)-L1 or C(O)-L1-NH, wherein L1 is as defined above. These compounds may be used to determine the activity of phospholipase A2, in particular PAF-AH.Type: GrantFiled: October 23, 2002Date of Patent: November 27, 2007Assignee: Sirs-Lab GmbHInventors: Hans-Peter Deigner, Stefan Russwurm, Ralf Kinscherf, Wolfgang Lösche
-
Publication number: 20050064532Abstract: What is described are compounds of formula (1) wherein L1 is derived from an ether (R1—OR2)m, wherein R1 and R2 are independently selected and are derived from a hydrocarbon having 1 to 12 carbon atoms, with m being an integer from 1 to 4, or from a hydrocarbon R having 1 to 20 carbon atoms; F is unsubstituted or substituted pyrene as a fluorophore; Q is a quencher, and L2 is C(O)-L1 or C(O)-L1-NH, wherein L1 is as defined above. These compounds may be used to determine the activity of phospholipase A2, in particular PAF-AH.Type: ApplicationFiled: October 23, 2002Publication date: March 24, 2005Inventors: Hans-Peter Deigner, Stefan Russwurm, Ralf Kinscherf, Wolfgang Losche
-
Patent number: 6790992Abstract: The present invention relates to novel scyphostatin analogues, which distinguish themselves by acting as SMase inhibitors so that they are of therapeutic use for a number of diseases such as a HIV infection, neurodegenerative diseases, inflammatory diseases, apoplexy, ischemia, myocardial infarction or in the case of atherosclerosis.Type: GrantFiled: August 22, 2002Date of Patent: September 14, 2004Assignee: Biofrontera Pharmaceuticals GmbHInventor: Hans-Peter Deigner